Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line and First-line Lower Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome Intervention:   Drug: OPN-305 Sponsors:   Opsona Therapeutics Ltd.;   M.D. Anderson Cancer Center;   Montefiore Medical Center;   H. Lee Moffitt Cancer Center and Research Institute;   New York Presbyterian Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials